Published in Health Business Week, June 18th, 2004
Howson previously served as a consultant to the company.
The company also announced that it has signed a letter of intent to divest its software migration tools business. Management expects to close the transaction, with a $500,000 purchase price, by the end of its current fiscal year ending July 31, 2004.
The appointment and the divestiture mark Accelr8's complete transition away from software and into medical diagnostic platforms that feature the company's surface chemistry and instrumentation technologies. This...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.